Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.70 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.70 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026416 | 0.92 | LMNA (0.72) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28403435 | 0.92 | LMNA (0.72) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL7919827 | 0.91 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL584613 | 0.91 | LMNA (0.70) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1683180 | 0.88 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL8740127 | 0.88 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL366600 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4946508 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5491562 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL30924912 | 0.86 | LMNA (0.53) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107474091-A | The synthesis and application of 5 aldehyde radical cytidine phosphoramidite monomers of photosensitive protective group protection and preparation method thereof and oligonucleotide | 南开大学 | 2017-12-15 | — | — | CN | claimed |
| CN-104011209-A | Inhibition Of Viral Gene Expression | UNIV WITWATERSRAND JHB | 2014-08-27 | — | — | CN | claimed |
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SYNERK BIOTECH LTD (HK) | 2026-02-12 | — | — | US | disclosed |
| EP-3765476-B1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-12428441-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-20 | — | — | US | disclosed |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12077757-B2 | Modified oligonucleotides and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-12030907-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118265801-A | Compositions and methods for improving 5-hydroxymethylated cytosine resolution in nucleic acid sequencing | 福瑞诺姆控股公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240011029-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | US | disclosed |
| EP-0724447-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-07 | — | — | EP | disclosed |
| EP-0724447-A4 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS INC (US) | 1996-01-22 | — | — | EP | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0618983-A1 | INSERTION ELEMENTS AND AMPLIFIABLE NUCLEIC ACIDS | AMOCO CORPORATION (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1994009159-A2 | INSERTION ELEMENTS AND AMPLIFIABLE NUCLEIC ACIDS | AMOCO CORPORATION (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993007883-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030907-B2 | Modified nucleoside phosphoramidites | PNP, TYMP, NSUN2 | LMNA 1464/4885THRB 2641/4885MTOR 2704/4885 |
| US-12077757-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | LMNA 754/4885THRB 1735/4885MTOR 4770/4885 |
| US-12428441-B2 | Modified nucleoside phosphoramidites | MTAP, PNP, NT5C3B | LMNA 957/4885THRB 4590/4885MTOR 2804/4885 |
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SSU72, NSUN2, RNMT | LMNA 275/4885THRB 1016/4885MTOR 4566/4885 |
| US-20240011029-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | LMNA 505/4885THRB 1861/4885MTOR 4786/4885 |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | NSUN2, ADAR, POLM | LMNA 808/4885THRB 1856/4885MTOR 4787/4885 |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | MTAP, PNP, NT5C3B | LMNA 957/4885THRB 4590/4885MTOR 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.